20 avril 2020 – Policy Brief

The role of serological testing in the COVID-19 response in Switzerland

Download Policy Brief PDF


Cette Policy Brief n’a pas été traduite.

The Krisenstab has asked the NCS-TF to look into the role of serological testing in the COVID-19 response. Several initiatives in Switzerland have sprung up to examine the seroprevalence of SARS-Cov-2 in the population. The Swiss School of Public Health (SSPH+) is planning a nationwide serological testing programme called « Corona Immunitas », using a large random sample of residents. A separate initiative, « Corona Immunity », targets testing of individuals. The action plans to launch rapid serological tests at home from May 2020, with support from business, politics, medicine and health insurance companies.

Executive summary

Serological studies, performed on blood samples, have the potential to provide information about the true number of people who have had a SARS-CoV-2 infection. The data allow robust estimates of infection mortality and morbidity in the general populationand in subgroups at increased risk of exposure. At the individual level, serological tests are proposed as a means to identify individuals who have developed immunity to SARS-Cov-2 and can return to work with low risk (“immunity passport”). This policy brief reviews the potentials and limitations of serology in Switzerland and outlines the priorities for future research.

The use of rapid to detect SARS-CoV-2 antibodies at the individual level is currently not indicated:

  • Prevalence of infection is low
  • The available tests have not been fully validated
  • There will be with many false positives if specificity is below 100%
  • Neutralising effect of antibodies not established.

The issue of “immunity passports” is problematic from a medical and ethical point of view. A recent study in Geneva established that the seroprevalence at the population level is low (around 5%), despite the high incidence of COVID-19 in Geneva compared to other cantons. The focus for research at the population level should, therefore, be on subpopulations at higher risk of infection. Test accuracy studies of different test types are another priority. Immunological studies of cellular and humoral immune response to SARS-CoV-2, to establish putative immune correlates of protection and the correlations between disease severity and antibody response, and to examine the duration of immunity are another important priority.

Date of request: 16/4/2020
Date of response: 20/4/2020

In response to request from: Krisenstab, Lukas Bruhin

Comment on planned updates: Planned

Expert groups and individuals involved: D&T, ELSI, PH, D. Trono, A. Trkola, L. Kaiser, C. Metzger, M. Stoffel, N. Low, S. Hurst, M. Egger

Contact persons: Didier Trono, Matthias Egger

La Swiss National COVID-19 Science Task Force ayant été dissoute au 31 mars 2022, plus aucune évaluation de la situation épidémiologique, mise à jour scientifique ou policy brief ne sera publiée à l’avenir. Toutes les publications, pages et informations antérieures de la Science Task Force restent disponibles sur ce site web.